Search | Clinical Trials Finder

Conditions: Multiple Myeloma
Interventions: Bendamustine, Bortezomib, Dexamethasone; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 13
States / cities: Thousand Oaks, California • Fort Myers, Florida • Baton Rouge, Louisiana + 9 more

Conditions: Metastatic Uveal Melanoma
Interventions: IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab, Dacarbazine; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 31
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more

Conditions: Small Cell Lung Cancer
Interventions: ABBV-706, Atezolizumab, Etoposide, Carboplatin, Lurbinectedin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 12
States / cities: New Haven, Connecticut • Gainesville, Florida • Ocala, Florida + 9 more

Conditions: Glioblastoma Multiforme
Interventions: Radiation Therapy, Temozolomide, Sorafenib; Radiation · Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 10
States / cities: Fort Myers, Florida • Gainesville, Georgia • Bethesda, Maryland + 7 more

Conditions: Adenocarcinoma of the Pancreas, Locally Advanced, Unresectable
Interventions: Gemcitabine, AMG 479, Placebo; Drug
Lead sponsor: NantBioScience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: San Francisco, California • Knoxville, Tennessee

Conditions: Non-Small-Cell Lung Carcinoma NSCLC
Interventions: MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 35
States / cities: Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 28 more

Conditions: Pancreatic Cancer
Interventions: BBR 3464; Drug
Lead sponsor: Theradex; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 9
States / cities: Tucson, Arizona • Berkeley, California • Chicago, Illinois + 6 more

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive
Interventions: Trastuzumab deruxtecan, Trastuzumab, Pertuzumab, Endocrine Therapy, Palbociclib; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Columbia, Maryland • Las Vegas, Nevada • Nashville, Tennessee + 2 more

Conditions: Non-small Cell Lung Cancer
Interventions: Ramucirumab, Necitumumab, Osimertinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV
Interventions: Atazanavir, Darunavir, Ritonavir, Optimized NRTI backbone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more

Conditions: Breast Cancer
Interventions: letrozole; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 20
States / cities: Berkeley, California • Long Beach, California • Hollywood, Florida + 17 more

Conditions: Breast Cancer
Interventions: Bosutinib, Letrozole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Whittier, California • Joliet, Illinois • Niles, Illinois + 2 more

Conditions: NSCLC Stage IV, Metastatic Non-Small Cell Lung Cancer
Interventions: Pembrolizumab, PEMETREXED, CARBOPLATIN, PACLITAXEL, InVision; Drug · Diagnostic Test
Lead sponsor: Julia K. Rotow, MD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Boston, Massachusetts • Brighton, Massachusetts • South Weymouth, Massachusetts

Conditions: Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
Interventions: XL184, temozolomide, Radiation Therapy; Drug · Radiation
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 8
States / cities: Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 5 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: cisplatin, paclitaxel, pemetrexed disodium, biologic sample preservation procedure; Drug · Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Scottsdale, Arizona • Tucson, Arizona

Conditions: ER-Positive HER2-Negative Breast Cancer
Interventions: Camizestrant, Ribociclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Duarte, California • Palo Alto, California • Marietta, Georgia + 9 more

Conditions: Small Cell Lung Cancer
Interventions: Irinotecan liposome injection, Topotecan; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 22
States / cities: Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 17 more

Conditions: Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
Interventions: Onvansertib, FOLFIRI, Bevacizumab, FOLFOX; Drug
Lead sponsor: Cardiff Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 41
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 35 more

Conditions: Prostate Cancer
Interventions: enzastaurin, placebo, docetaxel, prednisone; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 22
States / cities: Fullerton, California • Los Angeles, California • Northridge, California + 19 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: PF-3512676 + Paclitaxel + Carboplatin, Paclitaxel + Carboplatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 828 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 89
States / cities: Little Rock, Alaska • Hot Springs, Arkansas • Chula Vista, California + 69 more

Conditions: Extensive-stage Small Cell Lung Cancer
Interventions: BMS-986012, Carboplatin, Etoposide, Nivolumab; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 8
States / cities: Birmingham, Alabama • Hackensack, New Jersey • Durham, North Carolina + 4 more

Conditions: Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IA Ovarian Cancer AJCC v6 and v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IB Ovarian Cancer AJCC v6 and v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage IC Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7
Interventions: Bevacizumab, Capecitabine, Carboplatin, Laboratory Biomarker Analysis, Oxaliplatin, Paclitaxel, Quality-of-Life Assessment; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 248
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 163 more

Conditions: Metastatic Lung Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Pembrolizumab, Pemetrexed, Carboplatin, Comprehensive Geriatric Assessment, Questionnaire Administration, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 70 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 505
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 318 more

Conditions: Non-small Cell Lung Cancer NSCLC
Interventions: Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 9
States / cities: Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more

Search by objective public record fields.

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme

Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

BBR 3464 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot be Treated With Surgery

T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

Plasma-Adapted First-Line Pembro In NSCLC

Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma

Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)